AR092670A1 - Derivados de quinazolinona - Google Patents
Derivados de quinazolinonaInfo
- Publication number
- AR092670A1 AR092670A1 ARP130103430A ARP130103430A AR092670A1 AR 092670 A1 AR092670 A1 AR 092670A1 AR P130103430 A ARP130103430 A AR P130103430A AR P130103430 A ARP130103430 A AR P130103430A AR 092670 A1 AR092670 A1 AR 092670A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- replaced
- hal
- atoms
- piperazinyl
- Prior art date
Links
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- -1 4-isopropyl-1-piperazinyl Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000005959 diazepanyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación. Reivindicación 1: Compuestos de la fórmula (1) en donde: R¹, R² denotan cada uno, de modo independiente entre sí, H, F o Cl; R³ denota H, F, Cl, CH₃ u OCH₃; X¹, X² denotan cada uno, de modo independiente entre sí, CH o N; Y denota A, Cyc u oxiranilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, piperazinilo, piperidinilo, morfolinilo, pirrolidinilo, tiomorfolinilo o diazepanilo, que puede no estar sustituido o que puede estar mono- o disustituido con =O, Hal, OH y/o A; A denota alquilo C₁₋₄ no ramificado o ramificado, en donde un grupo CH₂ puede estar reemplazado por un átomo de O y/o un átomo de H puede estar reemplazado por OH; A denota alquilo C₂₋₁₀ no ramificado o ramificado, en donde dos átomos de carbono adyacentes pueden formar un enlace doble y/o uno o dos grupos CH y/o CH₂ no adyacentes pueden estar reemplazados por átomos de N, O y/o S y en donde 1 - 7 átomos de H pueden estar reemplazados por F, Cl y/u OH; Cyc denota cicloalquilo C₃₋₇, que no está sustituido o que está monosustituido con OH, Hal o A; Hal denota F, Cl, Br o I; siempre que al menos uno de R¹, R², R³ no sea H, y siempre que Y no sea 4-isopropil-1-piperazinilo, y sus sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092670A1 true AR092670A1 (es) | 2015-04-29 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103430A AR092670A1 (es) | 2012-09-26 | 2013-09-25 | Derivados de quinazolinona |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (es) |
| EP (1) | EP2900643B1 (es) |
| JP (1) | JP6276769B2 (es) |
| KR (1) | KR102200628B1 (es) |
| CN (1) | CN104662006B (es) |
| AR (1) | AR092670A1 (es) |
| AU (1) | AU2013324681B2 (es) |
| BR (1) | BR112015006524A8 (es) |
| CA (1) | CA2886000C (es) |
| ES (1) | ES2654464T3 (es) |
| HK (1) | HK1210777A1 (es) |
| IL (1) | IL237840A (es) |
| MX (1) | MX362855B (es) |
| RU (1) | RU2650107C2 (es) |
| SG (1) | SG11201502120XA (es) |
| WO (1) | WO2014048532A1 (es) |
| ZA (1) | ZA201502838B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| CN104302358B (zh) | 2012-03-07 | 2017-12-05 | 癌症研究协会:皇家癌症医院 | 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途 |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
| KR102327888B1 (ko) | 2012-12-21 | 2021-11-17 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CA2964113A1 (en) | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| WO2018204176A1 (en) * | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
| US11566017B2 (en) | 2017-12-27 | 2023-01-31 | Riken | Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor |
| JP7369968B2 (ja) * | 2017-12-27 | 2023-10-27 | 公益財団法人がん研究会 | 抗がん剤 |
| WO2021037868A1 (en) * | 2019-08-28 | 2021-03-04 | F. Hoffmann-La Roche Ag | Novel quinazoline compounds for the treatment and prophylaxis of hepatitis b virus disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| AU2003252314A1 (en) * | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| AU2006223469A1 (en) * | 2005-03-09 | 2006-09-21 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
| ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
| BRPI1009315B8 (pt) * | 2009-03-18 | 2021-05-25 | Resverlogix Corp | composto anti-flamatórios e suas composições farmacêuticas |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| PL2611300T3 (pl) * | 2010-09-03 | 2016-10-31 | Podstawione skondensowane pochodne dihydropirymidynonów |
-
2013
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en active Application Filing
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko active IP Right Grant
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
- 2015-11-24 HK HK15111558.4A patent/HK1210777A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2654464T3 (es) | 2018-02-13 |
| CA2886000C (en) | 2020-11-10 |
| AU2013324681A1 (en) | 2015-05-07 |
| MX2015003570A (es) | 2015-06-22 |
| CA2886000A1 (en) | 2014-04-03 |
| BR112015006524A2 (pt) | 2017-07-04 |
| IL237840A (en) | 2017-05-29 |
| KR20150063474A (ko) | 2015-06-09 |
| MX362855B (es) | 2019-02-20 |
| US20150239850A1 (en) | 2015-08-27 |
| BR112015006524A8 (pt) | 2019-08-20 |
| RU2015115576A (ru) | 2016-11-20 |
| AU2013324681B2 (en) | 2017-08-10 |
| KR102200628B1 (ko) | 2021-01-08 |
| JP2015535831A (ja) | 2015-12-17 |
| US9388142B2 (en) | 2016-07-12 |
| EP2900643B1 (en) | 2017-09-27 |
| WO2014048532A1 (en) | 2014-04-03 |
| SG11201502120XA (en) | 2015-04-29 |
| HK1210777A1 (en) | 2016-05-06 |
| JP6276769B2 (ja) | 2018-02-07 |
| EP2900643A1 (en) | 2015-08-05 |
| RU2650107C2 (ru) | 2018-04-09 |
| ZA201502838B (en) | 2017-11-29 |
| CN104662006B (zh) | 2017-10-24 |
| CN104662006A (zh) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092670A1 (es) | Derivados de quinazolinona | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR092366A1 (es) | Derivados de (aza-)isoquinolinona | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| UY35398A (es) | Compuestos de biarilamida como inhibidores de cinasa | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR090496A1 (es) | Derivados biciclicos de pirazinona | |
| AR100333A1 (es) | Derivados de heterociclil-butanamida | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR097086A1 (es) | Derivados 1,3-disustituidos de ciclopentano | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |